Medtronic Archives - Page 34 of 59 - Medical Design Sourcing

The 10 largest medtech employers of 2021 – and what their employees really think

Employees of the 10 largest medtech employers are proud of working on life-saving products — with a greater appreciation for diversity and inclusion initiatives.

That was one major takeaway as Medical Design & Outsourcing compiled some current and former employee reviews posted on Glassdoor. (Browse the online version of our Big 100 report.)

Despite the pride, there was also some frustration with big corporate bureaucracy.

Medtech employment in MDO‘s 2021 Big 100 was down slightly from our 2020 and 2019 reports — even as the industry continued to be on the frontlines of the COVID-19 pandemic. It’s worth noting that of the nearly 90 companies in this year’s Big 100 that provided employment data, about half added workers amid the pandemic. Another handful kept their headcounts the same.

The companies are the largest medical device industry employers in our most recent annual Big 100 list, which includes the top 100 medtech companies across the w…

The 10 largest medtech employers of 2021 – and what their employees really think

Employees of the 10 largest medtech employers are proud of working on life-saving products — with a greater appreciation for diversity and inclusion initiatives.

That was one major takeaway as Medical Design & Outsourcing compiled some current and former employee reviews posted on Glassdoor. (Browse the online version of our Big 100 report.)

Despite the pride, there was also some frustration with big corporate bureaucracy.

Medtech employment in MDO‘s 2021 Big 100 was down slightly from our 2020 and 2019 reports — even as the industry continued to be on the frontlines of the COVID-19 pandemic. It’s worth noting that of the nearly 90 companies in this year’s Big 100 that provided employment data, about half added workers amid the pandemic. Another handful kept their headcounts the same.

The companies are the largest medical device industry employers in our most recent annual Big 100 list, which includes the top 100 medtech comp…

Medtronic completes enrollment in pulsed-field ablation trial

Medtronic (NYSE:MDT) announced today that it completed patient enrollment its global pivotal Pulsed AF trial.

The Pulsed AF trial is evaluating the PulseSelect pulsed-field ablation (PFA) system in the prevention of the recurrence of AFib while avoiding unwanted injury to surrounding structures or tissue.

Fridley, Minnesota-based Medtronic conducted the first procedures of the Pulsed AF AFib treatment FDA investigational device exemption (IDE) trial in March after the FDA granted the company approval to move forward with the IDE trial to evaluate the safety and effectiveness of the PulseSelect in January 2020.

Medtronic designed PulseSelect to use electric fields to ablate or create lesions and scar tissue, interrupting irregular electrical pathways in the heart and the triggers of AFib. In contrast to traditional methods, PFA treatment is non-thermal and selectively targets cardiomyocytes (heart muscle cells) while avoiding other types of tissue in trea…

Health Canada licenses Medtronic’s GI Genius endoscopy module for colonoscopy

[Image from Medtronic]Medtronic (NYSE:MDT) announced today that it received Health Canada license for its GI Genius intelligent endoscopy module.

The company’s Brampton, Ontario-based Medtronic Canada subsidiary received the license for the computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

According to a news release, the GI Genius intelligent endoscopy module — which Medtronic touts as compatible with any colonoscope video — provides physicians with a tool to fight against colorectal cancer.

GI Genius uses advanced AI to highlight the presence of possible precancerous lesions with a visual marker in real-time. Advanced algorithms process the colonoscopy images to identify and mark polyp abnormalities, including ones that could otherwise go detected under the observation of the human eye.

…

Medtronic plans to bring next-gen diabetes tech to FDA this fiscal year, no spinoff planned

The Medtronic MiniMed 780G system. [Image from Medtronic]Medtronic (NYSE:MDT) confirmed that it anticipates major regulatory steps for its next-generation insulin pump and sensor during this fiscal year.

Speaking on the company’s second-quarter (fiscal year 2022) earnings call, Chairman & CEO Geoff Martha said Medtronic expects its MiniMed 780G insulin pump system with the Guardian 4 sensor for continuous glucose monitoring (CGM) to drive growth once approved, with the company currently in talks with the FDA.

Get the full story at our sister site, Drug Delivery Business News.

Supply chain, manufacturing issues slow Medtronic’s Hugo launch, ramp-up expected next fiscal year

Medtronic’s Hugo robot-assisted surgery system [Image courtesy of Medtronic]Medtronic (NYSE:MDT) Chairman & CEO Geoff Martha confirmed that the launch of the Hugo surgical robot platform is slightly off-schedule.

Speaking on the company’s second-quarter earnings call today, Martha said the launch of the platform, which the company has developed to challenge Intuitive Surgical in the surgical robotics space, is “not on-schedule but not off-track” at this stage.

Get the full story at our sister site, Medical Design & Outsourcing.

Supply chain, manufacturing issues slow Medtronic’s Hugo launch, ramp-up expected next fiscal year

Medtronic’s Hugo robot-assisted surgery system [Image courtesy of Medtronic]

Medtronic (NYSE:MDT) Chairman & CEO Geoff Martha confirmed that the launch of the Hugo surgical robot platform is slightly off-schedule.

Speaking on the company’s second-quarter earnings call today, Martha said the launch of the platform, which the company has developed to challenge Intuitive Surgical in the surgical robotics space, is “not on-schedule but not off-track” at this stage.

Hugo received CE mark approval last month and the company is gearing up to conduct its FDA investigational device exemption (IDE) clinical trials in the U.S., with more on the company’s stateside efforts still to come, President of Medtronic’s surgical robotics business, Megan Rosengarten, told MDO recently.

The launch that followed is currently in what Martha called a “limited-release phase” as the c…

Medtronic posts Q2 EPS beat, misses on revenues as U.S. sales dip

Medtronic (NYSE:MDT) shares dipped slightly before hours on second-quarter results that missed the consensus revenue forecast.

The Fridley, Minnesota-based medtech giant posted profits of $1.3 billion, or 97¢ per share, on sales of $7.8 billion for the three months ended Oct. 29, 2021, nearly tripling its bottom-line on sales growth of 2.6%.

Adjusted to exclude one-time items, earnings per share were $1.32, 3¢ ahead of Wall Street, where analysts were looking for sales of $8 billion.

Each of Medtronic’s major business arms saw year-over-year global revenue growth, with cardiovascular (up 3.7%) and neuroscience (3.5%) increasing the most. Medtronic’s diabetes business saw increased revenues of 1.9% and its medical surgical segment increased by 0.6%.

The largest dip came within the medsurg business, with the company’s respiratory, gastrointestinal and renal dealings dipping in revenues by 10.2%. Cranial and spinal technologies (wit…

FDA says cardiac perforation problems appear more severe with Medtronic’s Micra

The FDA earlier this week issued a letter highlighting certain complications associated with leadless pacemaker implantation, including with Medtronic’s (NYSE:MDT) Micra platform.

In the letter, the FDA noted that the overall risk of cardiac perforation associated with leadless pacemaker implantation appears similar to the risk associated with traditional transvenous pacing systems. Still, premarket clinical studies of Medtronic’s Micra have suggested that major complications related to cardiac perforation appeared more severe for patients with a leadless pacemaker compared to those with a transvenous one.

Real-world data suggest that cardiac perforations associated with Micra pacemakers are more likely to be associated with serious complications, including cardiac tamponade or death, when compared to traditional pacemakers, FDA said.

“Since the Micra Transcatheter Pacing System (TPS) received premarket approval in 2016, Medtronic has w…

The best places to work for medtech sales reps in 2022

Teleflex (NYSE:TFX), ConMed (NSDQ:CNMD) and Medtronic (NYSE:MDT) topped the list of best places to work in medtech sales in 2022, according to a MedReps.com survey of medical sales representatives.

The 11th annual MedReps survey polled over 2,300 MedReps professionals to determine which medtech sales companies are most sought-after in the industry.

Overall, pay and leadership were the most important considerations in an employer, followed closely by culture, according to the survey.

“Given the continued challenges medical sales reps faced in 2021, valuing leadership and culture in their place of work isn’t a surprise – and it’s important to recognize employers, like these companies on this list, that are doing much to support their employees,” MedReps CEO Josh Goodwin said in a news release. “We’re thrilled to highlight deserving employers to our community of medical sales professionals.”

Diversity, equity, inclusion and belonging was ranked as im…

The best places to work for medtech sales reps in 2022

Teleflex (NYSE:TFX), ConMed (NSDQ:CNMD) and Medtronic (NYSE:MDT) topped the list of best places to work in medtech sales in 2022, according to a MedReps.com survey of medical sales representatives.

The 11th annual MedReps survey polled over 2,300 MedReps professionals to determine which medtech sales companies are most sought-after in the industry.

Overall, pay and leadership were the most important considerations in an employer, followed closely by culture, according to the survey.

“Given the continued challenges medical sales reps faced in 2021, valuing leadership and culture in their place of work isn’t a surprise – and it’s important to recognize employers, like these companies on this list, that are doing much to support their employees,” MedReps CEO Josh Goodwin said in a news release. “We’re thrilled to highlight deserving employers to our community of medical sales professionals.”

Diversity, equity, inclusion and belonging was ranked as im…

How medtech fared in the first waves of the pandemic

[Photo by Martin Sanchez on Unsplash]Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data.

Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying the ongoing pandemic’s initial toll on the industry.

To compare performance before and during the pandemic, MDO used the financial data that we’ve historically gathered to rank our Big 100 companies in the last three years. The majority of these companies reported full-year results for 2020; others operate on a fiscal year and reported annual results in the first half of 2021.

Some companies are not in this year’s Big 100 but were included in the analysis because they were ranked in pre-pandemic years. The handful of companies that joined this yea…